O Shaughnessy Asset Management LLC Has $4.74 Million Holdings in GSK plc (NYSE:GSK)

O Shaughnessy Asset Management LLC decreased its holdings in GSK plc (NYSE:GSK) by 19.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,276 shares of the pharmaceutical company’s stock after selling 32,936 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in GSK were worth $4,744,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Primecap Management Co. CA increased its stake in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after buying an additional 10,407,905 shares during the period. Mondrian Investment Partners LTD boosted its holdings in GSK by 17.6% in the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after acquiring an additional 874,004 shares during the last quarter. Miller Howard Investments Inc. NY acquired a new stake in GSK during the 4th quarter valued at approximately $23,366,000. Equity Investment Corp raised its holdings in GSK by 13.3% during the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after purchasing an additional 466,327 shares during the last quarter. Finally, Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD acquired a new position in shares of GSK in the 4th quarter worth approximately $11,584,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GSK shares. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 0.6 %

GSK opened at $37.66 on Thursday. The company has a fifty day moving average price of $37.49 and a two-hundred day moving average price of $36.63. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a market cap of $77.95 billion, a P/E ratio of 23.69, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.18%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.